Suven Pharmaceuticals sells CR Bio assets for INR16 crore

Suven Pharmaceuticals, now Cohance Lifesciences Limited, announced today that it has entered into an agreement to sell the assets of its Clinical Research and Bio-analytical (CR Bio) unit to Chromo Laboratories India Private Limited for a total consideration of INR16 crore. The CR Bio unit, characterized as a non-core legacy asset, generated a revenue of INR9.8 crore in FY2025, constituting 0.82% of the company's standalone revenue. This transaction aligns with Suven’s strategic focus on its core CDMO operations. The deal is expected to close in Q2 FY2026, pending customary closing conditions. The company disclosed this information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.